Results 51 to 60 of about 3,126,313 (204)

Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia

Frontiers in Immunology, 2020
Essential thrombocythemia (ET) is comprised among chronic myeloproliferative neoplasms (MPN) and is caused by driver mutations in JAK2, CALR, and MPL, which lead to megakaryocyte proliferation and prominent thrombocytosis.
C. P. Marin Oyarzun, Ana C Glembotsky, N. Goette, P. Lev, Geraldine De Luca, M. C. Baroni Pietto, B. Moiraghi, M. C. Castro Ríos, Á. Vicente, R. Marta, M. Schattner, P. Heller   +11 more
semanticscholar   +1 more source

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]

, 2018
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet, Bennett, Cavan, Dovey, Oliver M, Ghevaert, Cedric, Gonzalez-Arias, Carlos, Green, Anthony R, Grinfeld, Jacob, Hamilton, Tina L, Kent, David G, Klampfl, Thorsten, Li, Juan, Loughran, Stephen, Park, Hyun Jung, Pask, Dean C, Prins, Daniel, Sneade, Rachel, Vassiliou, George S, Williams, Matthew   +17 more
core   +1 more source

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management

American journal of hematology/oncology
Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation‐prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications ...
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar   +1 more source

Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia

HemaSphere, 2020
Myeloproliferative neoplasms (MPNs) are characterized by deregulation of mature blood cell production and increased risk of myelofibrosis (MF) and leukemic transformation.
N. Øbro, J. Grinfeld, M. Belmonte, Melissa Irvine, Mairi S. Shepherd, T. N. Rao, A. Karow, L. M. Riedel, Oliva B. Harris, E. Baxter, J. Nangalia, A. Godfrey, C. Harrison, Juan Li, R. Skoda, P. Campbell, A. Green, D. Kent   +17 more
semanticscholar   +1 more source

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

Haematologica, 2013
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green   +5 more
doaj   +1 more source

Severe Case of Peripheral Leukocytosis Initially Diagnosed as Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, but Possibly Prefibrotic Primary Myelofibrosis [PDF]

, 2014
Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative disorders (MPD). A 74-year-old woman was admitted to our hospital for tarry stools, anemia, and marked peripheral leukocytosis of 1.4×105/μL ...
Hiramatsu, Yasushi, Kasahara, Akinori, Kondo, Eisei, Matsumura, Tadashi, Noguchi, Toshio, Ota, Seisuke, Takada, Saimon, Tanimoto, Mitsune, Umena, Sachio   +8 more
core   +1 more source

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Blood Cancer Journal
We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%
G. G. Loscocco, F. Gesullo, Giulio Capecchi, A. Atanasio, C. Maccari, F. Mannelli, A. Vannucchi, P. Guglielmelli   +7 more
semanticscholar   +1 more source

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep

Clinical Medicine Insights Blood Disorders, 2020
The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative Neoplasm characterized by a survival curve that is only slightly worse than that of age- and sex-adjusted healthy population.
V. Accurso, M. Santoro, S. Mancuso, M. Napolitano, M. Carlisi, Marta Mattana, C. Russo, A. Di Stefano, Davide Sirocchi, S. Siragusa   +9 more
semanticscholar   +1 more source

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development

Advanced Science, EarlyView.
Single‐cell RNA sequencing (scRNA‐seq) maps how distinct driver mutations remodel hematopoietic stem cell (HSC) programs across essential thrombocythemia (ET). Comparative analysis uncovers both shared and subtype‐specific molecular signatures, identifies a triple‐negative (TN)‐associated HSC population enriched with malignant traits, and reveals the ...
Jingyuan Tong, Di Wang, Haoze Song, Ting Sun, Yanhong Zhao, Wenjing Gu, Lexuan Lin, Yitong Zhao, Yipeng Liang, Xu Jin, Rongfeng Fu, Mankai Ju, Jie Gao, Jinfa Ma, Chengjie Gao, Anqi Zhang, Zhijian Xiao, Erlie Jiang, Renchi Yang, Shihui Ma, Lei Zhang, Lihong Shi   +21 more
wiley   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources